期刊文献+

DETECTION AND ITS CLINICAL VALUE OF MINIMAL RESIDUAL DISEASES IN ACUTE PROMYELOCYTIC LEUKEMIA

DETECTION AND ITS CLINICAL VALUE OF MINIMAL RESIDUAL DISEASES IN ACUTE PROMYELOCYTIC LEUKEMIA
下载PDF
导出
摘要 Objective: To detect the minimal residual diseases (MRD) in acute promyelocytic leukemia (APL) after complete remission (CR) and to analyze its clinical value in prognosis. Methods: Reverse transcription Polymerase chain reaction (RT/PCR) was used to detect MRD of patients with APL. Results: MRD positive rate in patients with APL was 92.8% (39/42) before treatment and 56.7 (21/37) immediately after the ATRA or chemotherapy-induced CR. Furthermore, MRD positive rate was related to the relapse in APL patients and could be considered as a marker to predict the relapse of patients with APL after CR. The MRD detection could also be applied to direct the consolidation therapy to prevent relapses. Conclusion: RT-PCR is valuable to monitor MRD and can be used as a marker to predict relapses. Objective: To detect the minimal residual diseases (MRD) in acute promyelocytic leukemia (APL) after complete remission (CR) and to analyze its clinical value in prognosis. Methods: Reverse transcription Polymerase chain reaction (RT/PCR) was used to detect MRD of patients with APL. Results: MRD positive rate in patients with APL was 92.8% (39/42) before treatment and 56.7 (21/37) immediately after the ATRA or chemotherapy-induced CR. Furthermore, MRD positive rate was related to the relapse in APL patients and could be considered as a marker to predict the relapse of patients with APL after CR. The MRD detection could also be applied to direct the consolidation therapy to prevent relapses. Conclusion: RT-PCR is valuable to monitor MRD and can be used as a marker to predict relapses.
出处 《Chinese Journal of Cancer Research》 SCIE CAS CSCD 2002年第4期288-292,共5页 中国癌症研究(英文版)
基金 This work was supported by the NaturalScience Foundation of Shandong Province (No. 2000.11) and a grant from the Science & Technology Committee of Shandong Province (No. 951228104).
关键词 APL PCR Minimal residual disease APL PCR Minimal residual disease
  • 相关文献

参考文献10

  • 1Fenaux P,ChevretS,GuerciA etal.long-term follow-up con-firm s the benefitofall-trans retinoic acid in acute prom yelocyticleukem ia[].European APL GroupLeukem ia.2000 被引量:1
  • 2WangZY,SunGL,LuJX,et al.Treatment of acute promyelocytic leukemia with all-trans retinoic acid inChina[].NouvRevFr hematol.1999 被引量:1
  • 3Bennett JM,catovsky D,Daniel MT,et al.proposals forthe classification of the acute leukendal French- American- British (FAB) cooperation group[].British Journal of Haematology.1976 被引量:1
  • 4LococoF,DiverioD,PandolfiPP,et al.Molecular evaluation of residual disease as a prodictor of relapse in acute promyelocytic leukemia[].The Lancet.1992 被引量:1
  • 5Geng JP,Tong JH,Dong Set al.Localication of the chromosome15 breakpoints and expression of multiple PML-RAR alpha transcriptsin acute promyelocytic leukemia:a study of28 Chinese patients[].Leukemia.1993 被引量:1
  • 6PandlfiPP,AlcalayM,FagioliM,et al.Genomic variability and alternative splicing generate multiplePML/RARa transcripts that encode aberrantPML proteins andPML/RARa isoforms in acute promyelocytic leukemia[].EMBO Journal.1992 被引量:1
  • 7Chen SJ,Chen Z,Chen A,et al.Occurrence of distinct PML--RARa fusion gene isoforms in patients with acute promyelocytic leukemia detected by reverse transcriptase/polymerase chain reaction[].Oncegene.1992 被引量:1
  • 8CastaigneS,ChomienneC,DanielMT,etal.All-transretinoicacidasadifferentiationtherapyforacutepromyelocyticleukemia.I.Clinicalresults[].Blood.1990 被引量:1
  • 9NigrinRS,BlumeKG.The use of polymerase chain reaction for the detection of minimal residual malignant disease[].Blood.1991 被引量:1
  • 10HoelzerD,ThielE,LofferH,et al.Prognostic factors in a multicenter study for treatment of acute lymphoblastic leukemia in adults[].Blood.1988 被引量:1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部